Related Experiment Video
Updated: Feb 28, 2026
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.8K
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation
Miguel Carnero-Gregorio1,2, Enzo Perera-Gordo1, Vanesa de la Peña-Castro3
1Department of Pathology, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Spain.
Genes
|February 27, 2026
Summary
Next-generation sequencing (NGS) identified actionable genomic alterations in over half of non-small cell lung cancer (NSCLC) patients. Smoking history did not exclude patients from comprehensive molecular testing for key drivers.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Next-generation sequencing (NGS) is standard for identifying actionable genomic alterations in non-small cell lung cancer (NSCLC).
- Real-world data on the genomic landscape of NSCLC in specific populations are crucial for guiding treatment strategies.
Purpose of the Study:
- To characterize the clinicopathological features and genomic landscape of a non-selected NSCLC cohort from the Canary Islands.
- To evaluate the feasibility and clinical utility of routine NGS testing in NSCLC.
Main Methods:
- Observational, retrospective study of 448 NSCLC tumors from 446 patients (March 2023-March 2025).
- Amplicon-based NGS panels (Oncomine™ Focus and Precision Assays) used for comprehensive genomic profiling (SNVs, indels, CNAs, fusions).
Main Results:
- Actionable alterations detected in 55.1% of tumors.
- Most frequent alterations: TP53 (29.5%), KRAS (27.2%), EGFR (14.1%). KRAS G12C was the most common variant.
- Significant prevalence of EGFR mutations (54.0%) and ALK fusions (50.0%) in smokers, challenging traditional exclusion criteria.
Conclusions:
- Routine NGS testing is feasible and clinically valuable for NSCLC.
- Genomic patterns in this cohort highlight the importance of comprehensive molecular testing regardless of smoking status.
